# Oligonucleotide Pool Market

> Oligonucleotide Pool Market Research Report Information By Type (DNA and RNA), By Application (Research, Diagnostic & Therapeutics, and Others), By End-User (Commercial Research, Pure Academic Research, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.3%
- **2024:** $ 1.67 Billion
- **2025:** $ 1.81 Billion
- **2035:** $ 4.02 Billion
- **Key Players:** Thermo Fisher Scientific (US), Integrated DNA Technologies (US), Agilent Technologies (US), Eurofins Genomics (DE), Biosearch Technologies (US), LGC Group (GB), Sigma-Aldrich (US), GenScript (CN), Twist Bioscience (US)

**Report ID:** MRFR/LS/1916-CR · **Pages:** 110 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** April 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/oligonucleotide-pool-market-2556

---

## Market Summary

## **Global Oligonucleotide Pool Market Overview**

The oligonucleotide pool market size was valued at USD 1.53 Billion in 2023. The oligonucleotide pool industry is projected to grow from USD 1.67 Billion in 2024 to USD 3.17 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.30% during the forecast period (2024 - 2032). 

Growing investment in oligonucleotide therapeutics for drug development by big pharmaceutical companies, increased involvement of CMOs in manufacturing therapeutic oligonucleotides, and increasing awareness about cell and gene therapy are the key market drivers enhancing the market growth.

Source Primary Research, _Market Research Future_ Database, Secondary Research, and Analyst Review

Waters Corporation has introduced OligoWorks SPE (solid-phase extraction) kits and components in October 2023 to enhance the preparation of samples for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides. The oligonucleotide recovery from biofluids can now be enhanced by up to a twofold over competing products for pharma and biopharma companies that are developing oligonucleotide therapeutics, as well as the Contract Research Organizations (CROs) that support them. The packages provide increased LC-MS sensitivity and reproducibility, which reduces the necessity for repeat experiments and enables lower limits of quantitation.

The pipeline for oligonucleotide therapeutics is expanding at a rapid pace, with 13 FDA-approved oligonucleotide therapeutics currently in circulation and over 500 more in the pipeline. 

Although efficacious, these highly modified oligonucleotides are difficult to precisely quantify during dosing, metabolism, and tissue distribution studies. OligoWorks SPE kits also employ an innovative, enzyme-enhanced, and detergent-free sample pretreatment that enables direct injection LC-MS analysis and lower limits of quantitation. This pretreatment reduces the number of rinsing steps and enhances mass spectrometer compatibility. Additionally, they can be entirely automated to enhance productivity or to assist scientists in reclaiming time by minimizing manual steps and oversight.

In November 2023, Twist Bioscience Corporation (NASDAQ: TWST), a company that empowers customers to achieve success by providing high-quality synthetic DNA through its silicon platform, introduced Twist Express Genes, a new, industry-leading gene synthesis service with a five- to seven-business-day turnaround time. Twist utilizes its silicon-based DNA synthesis platform, expertise, software, honed processes, and the expanded layout of its Wilsonville facility to deliver clonal genes and gene fragments at scale and with rapid turnaround times, thereby leveraging its ability to miniaturize the chemical reaction to create DNA.

Twist will implement dynamic pricing for Express Genes, charging a premium for speed that is contingent upon market demand and manufacturing capacity. Twist's ecommerce platform will enable customers to place orders for Express Genes. 

The length of Twist Express genes ranges from 0.3 to 5.0 kb. As with standard speed Twist Clonal Genes, Twist Express Genes are NGS sequence-verified as one hundred percent accurate, and orders of any size, big or small, can be filled as a result of the scale facilitated by Twist's platform. Customers can proceed directly to experimentation by cloning Twist Express Genes into catalog vectors or custom vectors. They can also be delivered in the preferred delivery format of the consumer, such as a tube or plate.

## **Oligonucleotide Pool Market Trends**

### **Increasing focus on new oligonucleotide therapies is driving the market growth**

Market CAGR for the oligonucleotide pool is being driven by the increasing focus on new oligonucleotide therapies. Pharmaceutical and biotechnological companies are focusing on the R&D of new oligonucleotide drugs due to the presence of a limited number of approved drugs. Oligonucleotides efficiently target disease-relevant proteins and genes inaccessible by small-molecule drugs and biological drugs. Recent advances have helped overcome challenges associated with the administration, cellular uptake, biodistribution, and side effects of oligonucleotide therapies. Many oligonucleotide therapeutics are in various clinical trials to treat many diseases, including viral infections, rare genetic disorders, neural and neuromuscular conditions, and cancers.

The presence of these drugs and an increase in R&D are expected to drive the oligonucleotide pool market revenue.

The increasing prevalence of chronic and life-threatening diseases has also prompted pharmaceutical companies and research firms to focus on R&D activities to develop effective therapeutics. As a result, life science research advances are leading to an improved understanding of biological systems. Developing oligonucleotide synthesis technologies has helped pharmaceutical and biotechnology researchers with molecular-level development, design, and modification of biological systems. The increasing research activities in the pharmaceutical and biotechnology sectors will expand the  market.

The emergence of oligonucleotide-based therapies increases the demand for oligonucleotide pool libraries. Oligonucleotides are poly nucleic acids made up of five base pairs called oligos. They work by changing the gene expression of the person they impact. Developing oligonucleotide-based therapies is evolving for various diseases, including respiratory diseases, cancer,[influenza,](../../../reports/influenza-diagnostics-market-3142)and STDs. Currently, only two oligonucleotide therapeutics are approved by the FDA, namely the antisense oligonucleotide Fomivirsen and the aptamer Macugen. The FDA has authorized several antisense medicines, the majority of which are used to treat rare illnesses such as Batten disease, CMV retinitis, Duchenne muscular dystrophy, and spinal muscular atrophy.

Initiatives taken by key players and government support are also playing a crucial role in the oligonucleotide pool library market growth. Many industry players are working on various strategies for emerging technologies for oligonucleotide pool libraries. The government also supports developing novel therapies based on genes for rare diseases. For instance, in August 2021, The News Agency of Nigeria (NAN) reported that Federal Government is expected to increase research and healthcare development investments to boost the health sector. Under this investment ministry of state, health is expected to inaugurate an oligo-synthesis laboratory.

## **Oligonucleotide Pool Market Segment Insights**

### **Oligonucleotide Pool Type Insights**

The oligonucleotide pool market segmentation, based on type, includes DNA and RNA. The DNA segment dominated the market, accounting for 35% of market revenue (0.54 Billion). In developing economies, category growth is driven by the significant utilization of DNA microarray technology and oligonucleotide for diagnostics therapeutics, and recent microchip-based oligonucleotide synthesis drives the market growth. However, RNA is the fastest-growing category due to the development of nonsensical RNA therapy in emerging economies.

### **Oligonucleotide Pool Application Insights**

The oligonucleotide pool market segmentation, based on application, includes research, diagnostic & therapeutics, and others. The diagnostic & therapeutics category generated the most income (70.4%) due to increasing focus on R&D activities by companies to develop novel diagnostic & therapeutics equipment in emerging economies. However, research is the fastest-growing category owing to the growing research and development activities for developing oligonucleotide pool drugs.

### **Oligonucleotide Pool End-User Insights**

The oligonucleotide pool market segmentation, based on end-user, includes commercial research, pure academic research, and others. The pure academic research category generated the most income due to surging healthcare spending capacity and advancement in healthcare infrastructure. However, commercial research is the fastest-growing category due to rising government investments in synthetic biology and genome projects.

**Figure 1 Oligonucleotide Pool Market by End-User, 2022 & 2032 (USD Billion)**

**_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_**

### **Oligonucleotide Pool Regional Insights**

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American oligonucleotide pool market area will dominate this market, owing to the presence of many market players and various developments done by them is the key factor driving the region's growth. Moreover, technological advancements, high investment in R&D, and rising demand for innovative oligonucleotide pools are other factors supporting the regional market. Further, the US oligonucleotide pool market held the largest market share, and the Canadian oligonucleotide pool market was the fastest-growing market in the European region.

Further, the prominent countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2** **Oligonucleotide Pool Market Share By Region 2022 (USD Billion)** ****

**_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_**

Europe's oligonucleotide pool market accounts for the second-largest market share owing to the growing number of companies operating in the region adopting various strategies, including research initiatives, product launches, and others, to propel the market growth. Further, the German oligonucleotide pool market held the largest market share, and the UK oligonucleotide pool market was the fastest-growing market in the European region.

The Asia-Pacific oligonucleotide pool market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to the presence of a large population and increasing awareness regarding the oligonucleotide pool. Moreover, China’s oligonucleotide pool market held the largest market share, and the Indian oligonucleotide pool market was the fastest-growing market in the Asia-Pacific region.

## **Oligonucleotide Pool Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development to expand their product lines, which will help the oligonucleotide pool market grow even more. Market participants are also undertaking numerous strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the oligonucleotide pool industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the oligonucleotide pool industry to benefit clients and increase the market sector. Major players in the oligonucleotide pool market, including Agilent Technologies, Creative Biogene, CustomArray, Inc., Integrated DNA Technologies, Inc., MYcroarray, Sigma-Aldrich Co. LLC, and others, are attempting to increase market demand by investing in research and development operations.

Pfizer Inc discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat cardiovascular, metabolic and pain conditions, women's health, cancer, inflammation, immune disorders, and rare diseases. It also delivers sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients and contract manufacturing services. Pfizer markets its products through wholesalers, retailers, hospitals, individual delivery offices, clinics, government agencies and pharmacies. It has prominent manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US.

In January 2021, Pfizer Inc., a pharmaceutical and Biotechnology company, announced that it had invested a total of US$ 120 million in 4 clinical-stage biotech firms, as part of the Pfizer Breakthrough Growth Initiative (PBGI), during the second half of the year 2020.

GSK plc (GSK) is a healthcare company focusing on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for treating diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases. GSK's vaccine portfolio covers various diseases, including hepatitis, tetanus, whooping cough, diphtheria, rotavirus and HPV infections, measles, and bacterial meningitis. The firm sells its products through wholesalers, pharmacies, hospitals, physicians and other groups ly.

In June 2022, GSK plc announced an approximately US$ 1.08 million investment over ten years to accelerate research and development (R&D) activities for infectious diseases that disproportionately impact lower-income countries.

### **Key Companies in the Oligonucleotide Pool market include**

- [Agilent Technology](https://www.agilent.com/en/product/oligo-pools-oligo-gmp-manufacturing/pooled-oligo-synthesis) (United States)
- Eurogentec S.A (Belgium)
- Merck Group (Germany)
- Illumnia Inc. (United States)
- LGC Biosearch Technologies (United States)
- Eurofins Genomics (Germany)
- Roche Sequencing (United States)
- Integrated DNA Technologies (United States)
- Nitto Denko Avecia Inc (United States)
- [General Biosystems](https://www.generalbiosystems.com/index.php/home/services/about/catid/48) (United States)

## **Oligonucleotide Pool Industry Developments**

November 2022: Celerion, a clinical research organization (CRO), expanded its molecular and cellular capabilities to Good Laboratory Practice/Good Clinical Practice standards to help the development of new modality therapies, such as cell and gene therapies. The expanded service offering is available in the company's locations, i.e., Lincoln and Zürich bioanalytical laboratories, including ELISpot analysis, flow cytometry, and qPCR. July 2022:  Eurofins Discovery acquired a contract research organization, DiscoveryBioMed, a life sciences and biotechnology company. This acquisition contributed to Eurofins Discovery's aim of offering various drug discovery services and products.

February 2021: The Centre for Process Innovation introduced an assignment in Medicine Manufacturing Innovation Centre in the UK. Via a partnership with AstraZeneca, Novartis, Exactmer, and UK Research & Innovation, this project seeks to change the synthesis of oligonucleotides. As a result of this contract, inclisiran, a small interfering RNA used to treat atherosclerotic cardiovascular disease (ASCVD), would be the first drug developed on a commercial scale

## **Oligonucleotide Pool Market Segmentation**

### **Oligonucleotide Pool Type Outlook**

- [DNA](../../../reports/dna-sequencing-market-5774)
- RNA

### **Oligonucleotide Pool Application Outlook**

- Research
- Diagnostic & Therapeutics
- Others

### **Oligonucleotide Pool End-User Outlook**

- Commercial Research
- Pure Academic Research
- Others

### **Oligonucleotide Pool Regional Outlook**

## Market Drivers

### Emergence of Synthetic Biology

The Oligonucleotide Pool Market is significantly impacted by the emergence of [synthetic biology](https://www.marketresearchfuture.com/reports/synthetic-biology-market-10901), which is reshaping the landscape of genetic engineering and biotechnology. This interdisciplinary field combines biology and engineering principles to design and construct new biological parts, devices, and systems. Oligonucleotide pools are essential in synthetic biology applications, enabling the creation of custom DNA sequences for various purposes, including metabolic engineering and gene editing. The market is expected to grow as synthetic biology gains traction, with estimates suggesting a growth rate of 18% over the next few years. This trend highlights the increasing reliance on oligonucleotide pools in pioneering biotechnological advancements.

### Rising Focus on Genetic Testing

The Oligonucleotide Pool Market is significantly influenced by the rising focus on genetic testing, which is becoming increasingly essential in clinical diagnostics and personalized medicine. As healthcare providers emphasize the importance of understanding genetic predispositions to diseases, the demand for oligonucleotide pools is likely to increase. These pools facilitate the development of assays that can identify genetic variations, thereby aiding in early diagnosis and treatment planning. The market is expected to expand as more healthcare systems adopt genetic testing protocols, with projections indicating a potential market growth of 15% annually. This trend underscores the critical role of oligonucleotide pools in enhancing patient care and outcomes.

### Growing Investment in Biotechnology

The Oligonucleotide Pool Market is poised for growth due to the increasing investment in biotechnology sectors. Governments and private entities are channeling funds into biopharmaceutical research, which often relies on oligonucleotide technologies for drug development and therapeutic applications. This influx of capital is likely to stimulate innovation and expand the market for oligonucleotide pools, with projections indicating a potential market size increase of 12% annually. As biotechnology continues to evolve, the demand for oligonucleotide pools will likely rise, driven by the need for novel therapeutic solutions and the development of advanced biotechnological products.

### Increasing Applications in Research and Development

The Oligonucleotide Pool Market is experiencing a surge in demand due to its increasing applications in research and development across various fields, including genomics, proteomics, and molecular diagnostics. Researchers are utilizing oligonucleotide pools for high-throughput screening, gene synthesis, and CRISPR technology, which are pivotal in advancing scientific knowledge. The market is projected to grow as more institutions invest in genomic research, with estimates suggesting a compound annual growth rate of over 10% in the coming years. This growth is driven by the need for innovative solutions in drug discovery and personalized medicine, where oligonucleotide pools play a crucial role in developing targeted therapies.

### Technological Advancements in Sequencing Techniques

The Oligonucleotide Pool Market is benefiting from rapid technological advancements in sequencing techniques, which are revolutionizing the way genetic information is analyzed. Innovations such as next-generation sequencing (NGS) and single-cell sequencing are driving the demand for oligonucleotide pools, as these technologies require high-quality, diverse oligonucleotide libraries for accurate results. The market is likely to see substantial growth, with estimates suggesting a valuation increase of over 20% in the next five years. These advancements not only enhance the efficiency of sequencing processes but also expand the applications of oligonucleotide pools in various research areas, including cancer genomics and rare disease studies.

## Future Outlook

The Oligonucleotide Pool Market is projected to grow at an 8.3% CAGR from 2025 to 2035, driven by advancements in genomics, increasing demand for personalized medicine, and expanding applications in research.

**New opportunities:**

- Development of customized oligonucleotide synthesis platforms Expansion into emerging markets with tailored product offerings Strategic partnerships with biotech firms for innovative applications

By 2035, the Oligonucleotide Pool Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: DNA (Largest) vs. RNA (Fastest-Growing)

In the Oligonucleotide Pool Market, DNA segments currently hold the largest market share, significantly contributing to the industry's overall revenue. This dominance is driven by the widespread use of DNA oligonucleotides in various applications such as gene synthesis, diagnostics, and synthetic biology. On the other hand, RNA oligonucleotides are emerging rapidly, with an increasing share of the market due to the rising interest in RNA therapeutics and the need for personalized medicine solutions.

Oligonucleotides: DNA (Dominant) vs. RNA (Emerging)

DNA oligonucleotides are considered the dominant type in the market, owing to their extensive applications in areas like gene editing, research, and diagnostics. Their ability to serve as powerful tools in genetic engineering reinforces their market position. Conversely, RNA oligonucleotides represent an emerging segment, gaining traction due to advancements in RNA-based therapies and the growing demand for innovative treatments. The increasing recognition of RNA's role in regulating gene expression and the surge in applications such as mRNA vaccines showcase their potential for substantial growth, making them a focal point for researchers and biopharmaceutical companies.

### By Application: Research (Largest) vs. Diagnostic & Therapeutics (Fastest-Growing)

The Oligonucleotide Pool Market exhibits a dynamic distribution among its application segments, primarily categorized into Research, Diagnostic & Therapeutics, and Others. The Research segment holds the largest market share, fueled by extensive academic and corporate research efforts aiming to innovate therapeutic solutions and diagnostic methodologies. This segment's robust growth is supported by a rising demand for genetic research, personalized medicine, and advancements in DNA sequencing technologies that require oligonucleotide pools for various experimental setups.

Research (Dominant) vs. Diagnostic & Therapeutics (Emerging)

The Research segment is characterized by its significant investment in molecular biology techniques, which drive the demand for oligonucleotide pools. It serves a broad array of purposes, including gene editing and synthetic biology applications. In contrast, the Diagnostic & Therapeutics segment is emerging rapidly, dominated by the need for customized therapies and molecular diagnostics. The increasing prevalence of genetic disorders and advancements in therapeutic oligonucleotides, particularly in personalized medicine, are catalyzing this sector's growth, indicating a shift in market dynamics as it gains traction and expands its share.

### By End-User: Commercial Research (Largest) vs. Pure Academic Research (Fastest-Growing)

The Oligonucleotide Pool Market exhibits a diverse distribution of market shares among its end-user segments. Commercial Research holds the largest segment share, driven by increasing investments from biotech and pharmaceutical companies in developing advanced therapeutic solutions. This segment capitalizes on significant funding and demand for customized [oligonucleotide synthesis](https://www.marketresearchfuture.com/reports/oligonucleotide-synthesis-market-2337) for research and diagnostic applications. On the other hand, Pure Academic Research is identified as the fastest-growing segment, reflecting an upward trend in funding from governments and private institutions. The rise in academic research initiatives focusing on genomics and molecular biology propels this segment, as researchers require extensive oligonucleotide pools for various experimental applications, thereby expanding its market footprint significantly over time.

Commercial Research: Dominant vs. Pure Academic Research: Emerging

Commercial Research segment stands out as the dominant player in the Oligonucleotide Pool Market. This sector is characterized by substantial investments in R&D from pharmaceutical and biotechnology firms, focusing primarily on drug development, personalized medicine, and genetic testing. The immense demand for high-quality synthetic oligonucleotides for various applications, including therapeutic development and diagnostic tools, is indicative of this segment’s strong market position. In contrast, Pure Academic Research is marked as an emerging segment, driven by rising academic interest in genetics and molecular studies. The availability of grants and funding for innovative research combined with a growing number of academic projects focused on oligonucleotides is facilitating rapid growth, thus contributing significantly to the overall dynamics of the market.

## Regional Market Share Analysis

### North America : Innovation and Research Hub

North America dominates the oligonucleotide pool market, accounting for approximately 45% of the global share. The region benefits from robust research and development initiatives, significant investments in biotechnology, and a strong regulatory framework that encourages innovation. The increasing prevalence of genetic disorders and the rising demand for personalized medicine are key growth drivers, further supported by government funding for genomic research. The United States is the largest market, followed by Canada, both hosting major players like Thermo Fisher Scientific and Integrated DNA Technologies. The competitive landscape is characterized by a mix of established companies and emerging startups, all vying for market share. The presence of leading institutions and universities enhances collaboration opportunities, fostering advancements in oligonucleotide technologies.

### Europe : Emerging Market with Growth Potential

Europe is witnessing significant growth in the oligonucleotide pool market, holding approximately 30% of the global share. The region's growth is driven by increasing investments in biotechnology and supportive regulatory frameworks that facilitate research and development. The European Medicines Agency (EMA) has been proactive in establishing guidelines that promote innovation in genetic therapies, which is expected to further boost market demand. Germany and the United Kingdom are the leading countries in this market, with a strong presence of key players like Eurofins Genomics and LGC Group. The competitive landscape is evolving, with numerous collaborations between academic institutions and industry players. This synergy is crucial for advancing oligonucleotide technologies and expanding their applications in therapeutics and diagnostics.

### Asia-Pacific : Rapidly Growing Market

Asia-Pacific is rapidly emerging as a significant player in the oligonucleotide pool market, accounting for about 20% of the global share. The region's growth is fueled by increasing investments in healthcare infrastructure, rising demand for personalized medicine, and a growing focus on genetic research. Countries like China and India are leading this growth, supported by government initiatives aimed at enhancing biotechnology capabilities and research funding. China is the largest market in the region, with a burgeoning biotechnology sector that includes key players like GenScript. The competitive landscape is characterized by a mix of local and international companies, all striving to capitalize on the growing demand for oligonucleotide products. The presence of numerous research institutions further accelerates innovation and development in this field.

### Middle East and Africa : Untapped Potential and Growth

The Middle East and Africa region is still in the nascent stages of the oligonucleotide pool market, holding approximately 5% of the global share. However, there is significant potential for growth driven by increasing investments in healthcare and biotechnology. Governments in the region are beginning to recognize the importance of genetic research and are implementing policies to support innovation and development in this sector. Countries like South Africa and the UAE are leading the way, with growing interest from both local and international players. The competitive landscape is evolving, with an increasing number of partnerships and collaborations aimed at enhancing research capabilities. As the region continues to develop its biotechnology infrastructure, the demand for oligonucleotide products is expected to rise significantly.

## Competitive Benchmarking

Leading market players are investing heavily in research and development to expand their product lines, which will help the oligonucleotide pool market grow even more. Market participants are also undertaking numerous strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the oligonucleotide pool industry must offer cost-effective items. Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the oligonucleotide pool industry to benefit clients and increase the market sector. Major players in the oligonucleotide pool market, including Agilent Technologies, Creative Biogene, CustomArray, Inc., Integrated DNA Technologies, Inc., MYcroarray, Sigma-Aldrich Co. LLC, and others, are attempting to increase market demand by investing in research and development operations. Pfizer Inc discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat cardiovascular, metabolic and pain conditions, women's health, cancer, inflammation, immune disorders, and rare diseases. It also delivers sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients and contract manufacturing services. Pfizer markets its products through wholesalers, retailers, hospitals, individual delivery offices, clinics, government agencies and pharmacies. It has prominent manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. In January 2021, Pfizer Inc., a pharmaceutical and Biotechnology company, announced that it had invested a total of US$ 120 million in 4 clinical-stage biotech firms, as part of the Pfizer Breakthrough Growth Initiative (PBGI), during the second half of the year 2020. GSK plc (GSK) is a healthcare company focusing on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for treating diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases. GSK's vaccine portfolio covers various diseases, including hepatitis, tetanus, whooping cough, diphtheria, rotavirus and HPV infections, [measles](https://www.marketresearchfuture.com/reports/measles-market-4449), and bacterial meningitis. The firm sells its products through wholesalers, pharmacies, hospitals, physicians and other groups ly. In June 2022, GSK plc announced an approximately US$ 1.08 million investment over ten years to accelerate research and development (R&D) activities for infectious diseases that disproportionately impact lower-income countries.

## Recent News & Developments

November 2022: Celerion, a clinical research organization (CRO), expanded its molecular and cellular capabilities to Good Laboratory Practice/Good Clinical Practice standards to help the development of new modality therapies, such as cell and gene therapies. The expanded service offering is available in the company's locations, i.e., Lincoln and Zürich bioanalytical laboratories, including ELISpot analysis, flow cytometry, and qPCR. July 2022:  Eurofins Discovery acquired a contract research organization, DiscoveryBioMed, a life sciences and biotechnology company. This acquisition contributed to Eurofins Discovery's aim of offering various drug discovery services and products.

February 2021: The Centre for Process Innovation introduced an assignment in Medicine Manufacturing Innovation Centre in the UK. Via a partnership with AstraZeneca, Novartis, Exactmer, and UK Research & Innovation, this project seeks to change the synthesis of oligonucleotides. As a result of this contract, inclisiran, a small interfering RNA used to treat atherosclerotic cardiovascular disease (ASCVD), would be the first drug developed on a commercial scale

## Report Scope

| MARKET SIZE 2024 | 1.67(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.809(USD Billion) |
| MARKET SIZE 2035 | 4.015(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.3% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Thermo Fisher Scientific (US), Integrated DNA Technologies (US), Agilent Technologies (US), Eurofins Genomics (DE), Biosearch Technologies (US), LGC Group (GB), Sigma-Aldrich (US), GenScript (CN), Twist Bioscience (US) |
| Segments Covered | Type, Application, End-User, Region |
| Key Market Opportunities | Advancements in personalized medicine drive demand for tailored Oligonucleotide Pool Market solutions. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the oligonucleotide pool market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Oligonucleotide Pool Market?**
A: As of 2024, the Oligonucleotide Pool Market was valued at 1.67 USD Billion.

**Q: What is the projected market size for the Oligonucleotide Pool Market by 2035?**
A: The market is projected to reach approximately 4.015 USD Billion by 2035.

**Q: What is the expected CAGR for the Oligonucleotide Pool Market during the forecast period?**
A: The expected CAGR for the Oligonucleotide Pool Market from 2025 to 2035 is 8.3%.

**Q: Which segments are included in the Oligonucleotide Pool Market analysis?**
A: The market analysis includes segments based on type, application, and end-user.

**Q: What are the projected valuations for DNA and RNA segments by 2035?**
A: By 2035, the DNA segment is projected to reach 2.01 USD Billion, while the RNA segment is expected to reach 2.005 USD Billion.

**Q: How do the applications of the Oligonucleotide Pool Market break down in terms of valuation?**
A: The Diagnostic & Therapeutics application is projected to reach 1.8 USD Billion, while Research applications are expected to reach 1.5 USD Billion by 2035.

**Q: What are the expected valuations for different end-users in the Oligonucleotide Pool Market?**
A: By 2035, Commercial Research is projected to reach 1.85 USD Billion, and Pure Academic Research is expected to reach 1.25 USD Billion.

**Q: Who are the key players in the Oligonucleotide Pool Market?**
A: Key players include Thermo Fisher Scientific, Integrated DNA Technologies, Agilent Technologies, and others.

**Q: What role do key players play in the growth of the Oligonucleotide Pool Market?**
A: Key players like Biosearch Technologies and Sigma-Aldrich contribute to market growth through innovation and product development.

**Q: What trends are influencing the Oligonucleotide Pool Market as it moves towards 2035?**
A: Trends such as increased research funding and advancements in diagnostic technologies are likely to drive market growth.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/oligonucleotide-pool-market-2556*